These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 23237448)

  • 1. [Imidazoline receptor agonists: are they actual today?].
    Nebieridze DV; Kamyshova TV
    Kardiologiia; 2012; 52(12):90-3. PubMed ID: 23237448
    [No Abstract]   [Full Text] [Related]  

  • 2. [The significance of the sympathetic nervous system during therapy for hypertension and related pathologies. Imidazoline-I1-receptor agonists. 17th Scientific Meeting of the International Society of Hypertension. Amsterdam, June 7, 1998].
    Dtsch Med Wochenschr; 1998 Aug; 123(33 Suppl):1-4. PubMed ID: 9739350
    [No Abstract]   [Full Text] [Related]  

  • 3. Imidazoline antihypertensive drugs: selective i(1) -imidazoline receptors activation.
    Nikolic K; Agbaba D
    Cardiovasc Ther; 2012 Aug; 30(4):209-16. PubMed ID: 21884004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Central nervous system as a target for the new antihypertensive agents].
    Nurminen ML
    Duodecim; 1999; 115(20):2267-73. PubMed ID: 11973931
    [No Abstract]   [Full Text] [Related]  

  • 5. Imidazoline Receptor Agonists for Managing Hypertension May Hold Promise for Treatment of Intracerebral Hemorrhage.
    Mahmoudi J; Majdi A; Lattanzi S; Di Napoli M; Bershad EM; Rodrigues CMP; Divani AA
    Curr Mol Med; 2018; 18(4):241-251. PubMed ID: 30259814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive treatment and sympathetic excitation.
    Malliani A; Montano N
    Hypertension; 2005 Sep; 46(3):e8; author reply e8. PubMed ID: 16123377
    [No Abstract]   [Full Text] [Related]  

  • 7. Selective imidazoline receptor agonists for metabolic syndrome.
    Krentz AJ; Evans AJ
    Lancet; 1998 Jan; 351(9097):152-3. PubMed ID: 9449863
    [No Abstract]   [Full Text] [Related]  

  • 8. [Renoprotecion With Metabolic Syndrome: the Possibility of Receptor Agonist Imidazoline Moxonidine].
    Ostroumova OD; Zykova AA
    Kardiologiia; 2016 Oct; 56(10):72-79. PubMed ID: 28290898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Hypertension and the sympathetic nervous system - recent developments in research and treatment].
    Grisk O
    Dtsch Med Wochenschr; 2009 Nov; 134(45):2289-93. PubMed ID: 19876804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Renal sequelae of sympathetic hyperactivity].
    Watschinger B; Habicht A
    Wien Med Wochenschr; 2004; 154 Spec No 1(1):7-9. PubMed ID: 15346546
    [No Abstract]   [Full Text] [Related]  

  • 11. High blood pressure management: potential benefits of I1 agents.
    Esler M
    J Hypertens Suppl; 1998 Aug; 16(3):S19-24. PubMed ID: 9747906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moxonidine: a new antiadrenergic antihypertensive agent.
    Prichard BN; Graham BR; Owens CW
    J Hypertens Suppl; 1999 Aug; 17(3):S41-54. PubMed ID: 10489098
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evidence that some imidazoline derivatives inhibit peripherally the vasopressor sympathetic outflow in pithed rats.
    Monroy-Ordoñez EB; Villalón CM; Cobos-Puc LE; Márquez-Conde JA; Sánchez-López A; Centurión D
    Auton Neurosci; 2008 Dec; 143(1-2):40-5. PubMed ID: 18774761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of selective imidazoline receptor agonists in modern hypertension management: an international real-world survey (STRAIGHT).
    Schlaich MP; Almahmeed W; Arnaout S; Prabhakaran D; Zhernakova J; Zvartau N; Schutte AE
    Curr Med Res Opin; 2020 Dec; 36(12):1939-1945. PubMed ID: 33047993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Centrally-acting antihypertensive drugs].
    Takishita S; Yamazato M
    Nihon Rinsho; 2004 Mar; 62 Suppl 3():591-5. PubMed ID: 15171442
    [No Abstract]   [Full Text] [Related]  

  • 16. Point: Chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension.
    Esler M; Lambert E; Schlaich M
    J Appl Physiol (1985); 2010 Dec; 109(6):1996-8; discussion 2016. PubMed ID: 20185633
    [No Abstract]   [Full Text] [Related]  

  • 17. [Possibilities of the use of moxonidine in the treatment of arterial hypertension in patients with metabolic syndrome and diabetes].
    Minushkina LO
    Kardiologiia; 2011; 51(4):74-8. PubMed ID: 21623724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sympathetic neural activity in hypertension and related diseases.
    Grassi G
    Am J Hypertens; 2010 Oct; 23(10):1052-60. PubMed ID: 20651696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autonomic nervous system activity changes in patients with hypertension and overweight: role and therapeutic implications.
    Valensi P
    Cardiovasc Diabetol; 2021 Aug; 20(1):170. PubMed ID: 34412646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rebuttal from Esler, Lambert, and Schlaich.
    Esler M; Lambert E; Schlaich M
    J Appl Physiol (1985); 2010 Dec; 109(6):2000-1. PubMed ID: 21148350
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.